anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Aim of the study: Polymorphisms of DNA repair enzyme gene may alter the ability of damage repair, ischemic stroke susceptibility and outcome. This study aimed to explore the association of polymorphisms in PARP1 and the effects of interactions between genes in Chinese.Materials and methods: A total of 500 patients and 500 healthy controls were enrolled for genotyping. Results: Clinical information analysis revealed higher levels of alcohol and smoking exposure in patients with ischemic stroke, as well as chronic conditions such as diabetes, hypertension, and higher serum triglycerides concentration. In addition, Polymorphism in PARP1 rs8679 was significantly associated with the decreased ischemic stroke risk. Patients harboring the PARP1 rs8679 AG/GG genotype had a better initial stroke, and as for the mRNA level of PARP1, it was suppressed with mutant genotype in comparison with the wild genotype. Finally, the suppressed of PARP1 was induced by gain-binding ability of miR-124-5p through 3'UTR directly binding.Conclusions: In conclusion, our study demonstrates that the SNP rs8679 in PARP1 3'-UTR might act as a protective factor for the outcome of patients with ischemic stroke.
PURPOSE:To obtain an antiulcer agent containing an amine derivative or a salt thereof and a sucrose fatty acid ester as active ingredients, having both of offensive factor suppressing action and defensive factor enhancing action and having excellent oral absorption effects. CONSTITUTION:The aimed composition containing an amine derivative expressed by the formula (R is 4-hydroxyphenyl, 4-carbamoylphenyl or 3- methanesulfonylaminophenyl group) or a salt thereof and a sucrose fatty acid ester as active ingredients. A naturally available sucrose fatty acid ester is preferably used as the sucrose fatty acid ester. The blend amount of saccharide fatty acid ester used is 0.1-10 times, preferably 0.25-5 times by weight based on the compound expressed by the formula or salt thereof. The title composition is obtained e.g. by a method dissolving or suspending the compound expressed by the formula and the sucrose fatty acid ester in a solvent such as water or phosphoric acid buffer.
Participants who achieve a CDAI reduction of \>=70 points from baseline at Week 12 will receive vedolizumab 300 mg IV infusion (monotherapy), every 8 weeks (Q8W) starting at Week 14 to 52. The Q8W vedolizumab monotherapy may be escalated to Q4W at the investigator's discretion.
A surgical device drive system comprising a gear coupled to a drive train is disclosed. The gear is configured to transmit a proximal retraction motion to a drive member. The surgical device drive system further comprises a control system coupled to the gear, and a manual input device comprising an input component and a ratchet mechanism. The input component is selectively coupled to the gear by the ratchet mechanism. The drive train is operable in a distal advancement direction and in a proximal retraction direction. In a first state, the control system is configured to drive the gear and the drive train in the distal advancement direction and the proximal retraction direction. In a second state, the manual input device is configured to drive the gear and the drive train in the proximal retraction direction, but not the distal advancement direction, using the ratchet mechanism.
OBJECTIVE: To investigate the outcomes of artificial urinary sphincter (AUS) placement in patients with post-prostatectomy urinary incontinence (PPUI) with or without a prior male sling.
PATIENTS AND METHODS: We performed a retrospective chart review of patients who underwent AUS for PPUI from 2007 to 2022. The primary endpoint was to determine the proportion of patients who achieved social continence, defined as self-reported use of 0-1 pad/day. The secondary endpoints were device failure rates and device failure-free survival.
RESULTS: The analysis included 210 patients, with 30 (14.3%) having had prior slings and 180 (85.7%) without prior slings. After AUS insertion, 80.0% of patients with prior slings and 76.7% of those without prior slings achieved continence (0-1 pad/day). There were six (20.0%) and 53 (29.4%) device failures in patients with and without prior slings, respectively. The median device failure-free survival was not reached in patients with prior slings and was 8.9 years in patients without prior slings (P = 0.048). Limitations include retrospective nature and small sample size.
CONCLUSIONS: The efficacy and safety of AUS in patients with prior slings are similar to those without. Prior sling is associated with a longer device failure-free survival. AUS remains a viable option in patients who have persistent PPI after prior slings.
Roujin Formula : angelica, bupleurum, radix paeoniae alba, etc. Medication method : oral 1 bag ( 150ml ) each time, 2 times a day. Treatment course : 8 weeks.
Participants in Observation Phase will receive their treatment prescribed by treating physicians as part of their routine clinical practice and the standard of care (SoC) treatment for Rwanda mental healthcare settings. Participants who have not received risperidone or paliperidone or paliperidone palmitate earlier in Observation Phase will receive oral risperidone 3 milligram (mg) tablets once daily for 3 days in Run-in Phase to determine tolerability. Participants will receive flexible dose range from 50 to 150 mg equivalent (eq.) long acting formulation of paliperidone palmitate once monthly (PP1M) as an intramuscular (IM) injection in Lead-in Treatment Phase for at least 17 weeks (maximum 25 weeks) and if stable dose is achieved for PP1M, participants will enter Maintenance Treatment Phase and continue to receive flexible dose range from 175 to 525 mg eq. long acting formulation of paliperidone palmitate every 3 months (PP3M) as an IM injection for up to 24 weeks.
The starting dose was 30 mg/m2 IV and the subsequent dose was increased according to the protocol of 60 mg/m2, 90 mg/m2, 120 mg/m2, 150 mg/m2, 180mg/m2. The interval between the first dose and the second dose was 3 weeks, followed by 2 weeks.
Patients will be randomized to the intervention group after they have complete the study screening form. Patients randomized to the intervention group will receive a multifaceted intervention consisting of the following components (administered over an 8 week period): (1) Web-Based Cognitive Behavioral Therapy: (2) Short Questionnaires; (3) Ongoing Nurse Monitoring.
INTRODUCTION: It is unclear whether kidney/pancreas (KP) transplantation will prevent the progression of peripheral arterial disease (PAD) in patients with insulin dependent diabetes (IDDM) and end-stage renal disease. We sought to determine the pre- and posttransplant prevalence of symptomatic PAD and changes in carotid artery intima-media thickness (IMT) in KP recipients.
METHODS: In this single center study, outcomes were compared between KP recipients with and without a history of PAD. A subset of recipients underwent pre- and posttransplant IMT measurements.
RESULTS: Among the study group (N = 107), 18 (17%) recipients admitted to a pretransplant history of symptomatic PAD, comprised 11 foot infections and 7 amputations (5 minor and 2 major). Baseline characteristics of age, gender, race, years of diabetes, dialysis history, smoking history, years of hypertension, and history of coronary artery disease (CAD) were equivalent between PAD and non-PAD cohorts. At a median follow-up of 60 months (IQR: 28, 110), 16 (15%) KP recipients had suffered a PAD event. In multivariate analysis, a pretransplant history of PAD (hazard ratio [HR] 9.66, p < 0.001) and CAD (HR 3.33, p = 0.04) were independent predictors of posttransplant PAD events. Among a subset of 20 recipients (3 with PAD), mean IMT measurements pretransplant and at a median of 24 (range 18-24) months posttransplant, showed no evidence of disease progression.
CONCLUSION: Based on IMT measurements and clinical results, KP transplantation stabilized PAD in most patients, but did not alter outcomes of symptomatic PAD recipients. A pretransplant history of PAD and CAD was an independent predictor of posttransplant PAD events.
With the accelerated pace of the global aging society, the prevalence of degenerative diseases is increasing. At present, spinal degenerative diseases caused by body degeneration have become the most common type. With the continuous deepening of the research on spinal degenerative diseases and the continuous development, update and promotion of minimally invasive surgery technology and instruments, minimally invasive surgery has attracted more and more attention of spine surgeons due to its advantages of rapid recovery, small trauma and fewer complications.

The core of endoscopic spinal surgery is nerve root decompression. The procedure is centered on the nerve roots, which can be damaged with the slightest carelessness. According to statistics, the incidence of nerve root injury under spinal endoscope is 1.8-2.5%. Most of the injuries include the stimulation and edema of the nerve root during the operation, which may lead to postoperative sensory retardation and motor weakness, which will damage the patient's physical function and reduce overall satisfaction. The intraoperative nerve exploration is time-consuming and critical, and the variability of the patient's nerve anatomy will also add difficulties to the operation. A real-time auxiliary intraoperative nerve identification technology is necessary.

With the progress of optical technology, fluorescent-guided surgery has shown considerable prospects in assisting in identifying nerves. Indocyanine green (ICG) is the only fluorophore approved by the US Food and Drug Administration (FDA) for intraoperative near-infrared imaging. It can emit near-infrared light after being irradiated by excitation light, which has the characteristics of high penetration depth, low spontaneous fluorescence and high sensitivity. At present, ICG near-infrared fluorescence imaging has been applied to tumor detection, lymphangiography and vascular perfusion evaluation. In recent years, more and more researchers have paid attention to the application value of ICG fluorescence imaging in neuroimaging. It has been applied to clinical research of thoracic sympathetic ganglion, facial nerve, phrenic nerve and pelvic nerve.
PURPOSE:To allow the treatment effective to the human body by a synergistic effect by forming the treating material which has effective treatment parts disposed with germanium and ceramics which radiates far IR rays by heating within specific distances to at least a part of the material. CONSTITUTION:The sheet-like cutaneous contact treating material has the effective treatment parts disposed with the germanium and the ceramics within at least max. 3cm distance in at least a part thereof. The effective treatment parts may be provided continuously over the entire part of the sheet or provided discontinuously and may be preferably so formed that the weight ratio of the germanium (as pure inorg. germanium and hereinafter the same): ceramics attain 3 to 40:97 to 60. The effective treatment parts may be one or plural. The treatment part is provided by dispersing a powder mixture composed of, for example, fine metal powder of the germanium and the fine sintered powder of the ceramics into a suitable solvent, mixing this dispersion with an adhesive agent of an acrylic resin system, polyurethane resin system, etc., to prepare a coated film liquid, applying such liquid to suitable yarn 10 and weaving a fabric with the yarn obtd. after the solvent is removed or providing the yarn as a non-woven fabric.
Consumption of a portion of Eat Balanced pizza equivalent to 200 µg of iodine (half a pizza) consumed with 450 mL water. Collection of urine for 36 hours following pizza ingestion. Collection of one fecal sample up to 24 hours following pizza ingestion.
Participants will receive 6 infusions of Prochymal® 2x10\^6 human mesenchymal stem cells (hMSC)/kg IV during the first 4 weeks of the study. The first infusion will be administered within 72 hours of the start of systemic corticosteroid therapy. Participants will receive 4 infusions during the first 2 weeks (twice weekly at least 3 days apart), followed by 2 infusions administered once weekly over the subsequent 2 weeks up to Day 28.
PURPOSE: A composition for oral hygiene is provided to suppress biofilm generation, to effectively remove the biofilm which causes bad breath, dental erosion, dental calculus formation, and gingival diseases, to prevent and treat bad breath and gingival diseases(ulitis), and to effectively maintain and treat dental health. CONSTITUTION: A composition for oral hygiene contains 0.01-1.0 parts by weight of a Machilus thunbergii extract and 0.1-10 parts by weight of a sequestrant as active ingredients. The composition suppresses generation of a biofilm or removes the biofilm. The sequestrant is a phosphate-based compound. Toothpaste contains the Machilus thunbergii extract and the sequestrant as active ingredients. The toothpaste suppresses generation of the biofilm or removes the biofilm.
LINC00857 is frequently dysregulated in varying cancers, which in turn exerts carcinogenic effects; however, its DNA methylation status in promoter region and molecular mechanisms underlying the progression of lung adenocarcinoma (LUAD) remain rarely understood. Through bioinformatics analysis, we examined the expression state and methylation site of LINC00857 in LUAD and further investigated the properties of LINC00857 as a competitive endogenous RNA in the cancer progression. The current study revealed that the overexpression of LINC00857 in LUAD tissue and cells was mainly caused by the hypomethylation of the promoter region. LINC00857 knockdown prominently reduced cell proliferation, impeded cell migration and invasion, and restrained lymph node metastasis, with enhancing radiosensitivity. The effects of LINC00857 on tumor growth were also investigated in nude mice models. Subsequently, the downstream factors, miR-486-5p and NEK2, were screened, and the putative regulatory axis was examined. Overall, the regulatory effect of methylation-mediated LINC00857 overexpression on miR-486-5p/NEK2 axis may be a new mechanism for LUAD progression.
This study will test the effects of two different diets on the immune system and inflammation in diabetes and pre-diabetes. These diets are the "Anti-Inflammatory Diet" (AI Diet) used by many naturopathic doctors and a standard diabetic diet based on the American Diabetes Association recommendations (ADA Diet). The AI diet excludes wheat, dairy products, eggs, red meat, caffeine, alcohol, peanuts and certain fruits and vegetables. The ADA diet includes most foods but controls the amount of each of the food groups.

Naturopathic physicians often use healthful diets to treat diseases but many of these diets have not been compared to usual medical diet treatments. We will be looking at blood markers that show how the immune system responds to the different diets. We are expecting that the AI diet will result in less inflammation and a better response by the immune system than the ADA diet. We will also be looking at levels of blood lipids and glucose to see any effects on these risk factors.
Immune-mediated sinusitis is poorly described and may easily go undiagnosed. We conducted a retrospective, multicenter, national study focusing on symptomatic immune-mediated sinusitis in patients receiving immune checkpoint inhibitors (ICIs) for melanoma treatment. Twelve patients were included (50% women, median age 58 years). Overall, the paraclinical assessment, the inefficacy of antibiotic/antihistaminic treatment, the improvement of symptoms on immunosuppressants and/or after ICI discontinuation, and the presence of multiple concomitant immune-related adverse-events, suggested a noninfectious etiology. Recognizing this toxicity is imperative for limitation of diagnostic wandering and appropriate treatment. However, additional epidemiological studies are needed to assess its prevalence as a potential immune-related adverse-event, and its prognostic value in patients treated with ICIs.
Endotracheal aspirates, blood samples, urine samples, and nasopharyngeal swabs were obtained from the patients as soon as possible after ICU admission. Bacterial culture was performed, with the use of standard techniques, on blood samples and endotracheal aspirates. Urine antigen detection was performed for detection of L. pneumophila and S. pneumoniae. A PCR assay was performed on nasopharyngeal swabs for the detection of influenza A and B viruses and SARS-CoV-2 viruses. Fungal or mycobacterial detections, and whether to use multiplex PCR for pathogen detection, such as the FilmArray system, were determined at the discretion of the physicians.
PURPOSE:To provide the subject adsorbent great in adsorbing power, eliminating no pesticide adsorbed even under coexistence of other adsorbent(s), causing no vomiting even if taken, also excellent in molding processability. CONSTITUTION:The objective adsorbent or antidote for pesticides, containing, as active ingredient, a hydrophobic polyamino acid (pref. polyleucine). Use of this hydrophobic polyamino acid as antidote finds application to detoxication of a wide range of pesticides; thus being advantageous for first aid even in case the type of pesticides in question cannot be identified. Also, the hydrophobic amino acid is a material inert to the human body; therefore, having such advantages that, even after orally administered, this compound does not irritate the mucous membrane of the esophagus and stomach, resulting in being seldom vomitted. Besides, the adsorbent of the present invention is easy in molding processing, and can be used in the suction protective masks or clothing in pesticide application.
Provided are drug delivery compositions and devices useful for the treatment and/or prevention of cancer and metastatic tumors. For example, a drug delivery composition and/or device is provided that comprises a biodegradable scaffold or biomaterial comprising one or more agents that inhibit one or more proinflammatory pathways, such as one or more immune responses mediated by a p38 mitogen-activated protein kinase (MAPK) pathway. In some embodiments, a drug delivery composition and/or device may further comprise one or more agents that activate the innate immune system (e.g., STING agonists) and/or the adaptive immune system (e.g., anti-PD-1 antibodies). In some embodiments, a drug delivery composition and/or device may include a cytokine (e.g., IL-15 superagonist). In some embodiments, a drug delivery composition and/or device can be administered to a tumor resection site (e.g., a void volume resulting from a tumor resection). Such intraoperative administration can prevent tumor regrowth and/or tumor metastasis. Also provided are methods of making drug delivery compositions and devices as well as kits containing materials to provide the same.
The invention relates to a medicine for tranquilizing and allaying excitement, which belongs to the field of traditional Chinese medicines. The invention aims to provide the medicine for tranquilizing and allaying the excitement, which aims at achieving the effect of sleeping peacefully by adopting the theory of traditional Chinese medicine through tranquilizing, allaying the excitement, nourishing the heart, calming the mind, invigorating qi and producing blood. The medicine for tranquilizing and allaying the excitement comprises the following raw materials for preparing effective components: pearl, dragon's bone, spina date seed, polygala tenuifolia, poria with hostwood, rhizoma acori graminei, angelica, white peony root, astragalus root and mugwort leaf. The medicine for tranquilizing and allaying the excitement is simple to prepare and has low price, a good curative effect, no toxic or side effect, a short treatment time and good social and economic benefits. Various medicines are matched. The medicine for tranquilizing and allaying the excitement aims at the symptoms of difficulty in falling asleep, dreaminess, festless sleep and the like, which are caused because of heart disturbance by liver fire, heart-spleen deficiency, fire excess from yin deficiency, internal disturbance by phlegm heat, timidity due to the insufficiency of qi and the deficiency of the blood of the heart and the like, so as to achieve the effect of sleeping peacefully by tranquilizing, allaying the excitement, nourishing the heart, calming the mind, invigorating qi and producing blood.
The invention provides a streptococcus suis cell wall hydrolase as well as a coding gene and an application thereof, and relates to the field of biotechnologies. The amino acid sequence of the streptococcus suis cell wall hydrolase is as shown in SEQ ID NO:1. The invention further discloses the coding gene of the streptococcus suis cell wall hydrolase and a recombinant expression vector and a recombinant bacterium containing the streptococcus suis cell wall hydrolase. The invention provides a method for preparing the streptococcus suis cell wall hydrolase. The streptococcus suis cell wall hydrolase is obtained through cultivating the recombinant bacterium and then purifying. The streptococcus suis cell wall hydrolase can effectively kill streptococcus suis, escherichia coli, staphylococcus aureus and aeromonas hydrophilia. The gene of the streptococcus suis cell wall hydrolase can be efficiently expressed in recombinant escherichia coli, and the activity and stability of the obtained streptococcus suis cell wall hydrolase are high, so that the streptococcus suis cell wall hydrolase can effectively kill streptococcus suis, escherichia coli, staphylococcus aureus and aeromonas hydrophilia.
OBJECTIVE: This study compared clinical pain outcomes between patients in a pain treatment program that was conducted in-person, compared with a virtual program.
METHODS: In-person (N=127) and virtual (N=101) pain treatment programs were compared based on patient-reported, practitioner-collected, and medical record data. The patients were measured at baseline and post-treatment (week 12 for In-Person and week 8 for Virtual patients). We employed the last observation carried forward (LOCF) to handle missing data.
RESULTS: Both the In-Person and Virtual groups were similar in regard to all baseline outcomes, except the In-person group having significantly more co-morbidities at baseline, with particularly more cases of mental, behavioral, or neurodevelopmental diseases. Both groups demonstrated significant improvements in the pain-related measurements of pain interference and pain catastrophizing thoughts, but neither group displayed a change in average pain across treatment. Further, both groups improved significantly on emotional well-being scores, but not on physical functioning scores. No significant differences existed between groups on outcomes, except for pain catastrophizing, which was higher in the Virtual group at both time points. The Virtual group had lower rates of dropouts compared with In-Person, while the In-Person group had a larger proportion reach a clinically meaningful change in pain-related outcomes, defined as a >30% improvement.
DISCUSSION: While some changes were unique to the In-Person program, overall, patients in the Virtual program achieved similar treatment outcomes, suggesting that it can successfully treat Veterans seeking pain management, with less need for in-person facilities for both patients and clinicians.